A
A
    Global websites
    Local websites
    language header world map

    argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

    News
    January 6, 2025
    argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
    argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

    Amsterdam, the Netherlands

    argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT.

    A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

    Downloads
    argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

    About argenx

    argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.

     

    For further information, please contact:

    Media:

    Ben Petok
    bpetok@argenx.com

    Investors:

    Alexandra Roy (US)
    aroy@argenx.com

    Lynn Elton (EU)
    lelton@argenx.com